Eastgate Biotech Corp (fka ETBI)

[02opida]

WEST CALDWELL, NJ and TORONTO, ON / ACCESSWIRE / April 17, 2018 / EastGate Biotech Corp. (OTC PINK: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of type 2 diabetes, announced a joint venture agreement with Netris/Origin Biopharmaceuticals (Netris/Origin) to conduct clinical trials, register, and commercialize the Netris/Origin pipeline for the Pakistani market.

Under the terms of the agreement, EastGate Biotech will retain a majority stake in the joint venture and will grant an exclusive right to Netris/Origin to conduct the clinical trials, registration and commercialization of EastGate's biotech products and product candidates in Pakistan. The focus of the JV is the development of EastGate's liquid insulin mouth solution whereby Netris/Origin will bear all of the costs in order to conduct all the necessary clinical and regulatory steps to receive regulatory and marketing approval for Pakistan